구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Belantamab Mafodotin-Blmf |
Overview Company | GSK |
Overview Modality | ADC |
Overview Target | Multiple Myeloma |
Overview Indication | Multiple Myeloma; Neoplasms |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Long-lasting effect of belantamab mafodotin in heavily pretreated multiple myeloma.. Belantamab mafodotin (BLMF) is an interesting therapeutic alternative for multiple myeloma (MM) patients pretreated with immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies. Scientific evidence on BLMF provides immature data about progression-free survival and overall survival by sho… |
Clinical Safety signal | Long-lasting effect of belantamab mafodotin in heavily pretreated multiple myeloma.. Belantamab mafodotin (BLMF) is an interesting therapeutic alternative for multiple myeloma (MM) patients pretreated with immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies. Scientific evidence on BLMF provides immature data about progression-free survival and overall survival by sho… |
Clinical Selected reported efficacy | ORR 6% |
Clinical Reported ORR | 6% |
Clinical Result source | ClinicalTrials.gov NCT05986682 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT05986682 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Belantamab Mafodotin-Blmf |
Overview Company | GSK |
Overview Modality | ADC |
Overview Target | Multiple Myeloma |
Overview Indication | Multiple Myeloma; Neoplasms |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Long-lasting effect of belantamab mafodotin in heavily pretreated multiple myeloma.. Belantamab mafodotin (BLMF) is an interesting therapeutic alternative for multiple myeloma (MM) patients pretreated with immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies. Scientific evidence on BLMF provides immature data about progression-free survival and overall survival by sho… |
Clinical Safety signal | Long-lasting effect of belantamab mafodotin in heavily pretreated multiple myeloma.. Belantamab mafodotin (BLMF) is an interesting therapeutic alternative for multiple myeloma (MM) patients pretreated with immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies. Scientific evidence on BLMF provides immature data about progression-free survival and overall survival by sho… |
Clinical Selected reported efficacy | ORR 6% |
Clinical Reported ORR | 6% |
Clinical Result source | ClinicalTrials.gov NCT05986682 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT05986682 |
추천 비교
추천 비교